Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Corporation

Edwards Lifesciences Italia

Edwards Lifesciences Europe

Edwards Hemodynamic Monitoring

Edwards Surgical Structural Heart Therapies

Edwards Lifesciences España

Edwards Lifesciences (NYSE: EW), is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. We thrive on discovery and expanding the boundaries of medical technology, serving patients in 100+ countries, with the help of our employees in areas including Clinical Affairs, Quality Engineering, Research & Development, Regulatory Affairs, Sales & Marketing, corporate functions and more.

Our roots date back to 1958 when Miles Lowell Edwards, a retired engineer with a background in hydraulics and fuel pump operations, set out to build the first artificial heart. Edwards believed the heart could be mechanized and was encouraged by Dr. Albert Starr to focus on developing an artificial heart valve. After just two years, the first Starr-Edwards mitral valve was developed and successfully placed in a patient. This innovation spawned Edwards Laboratories. Miles’ fascination with healing the heart and helping patients with heart disease stemmed from his own experience with rheumatic fever as a teenager and continues to fuel our patient-first culture today.

Today, we are as passionate about providing innovative solutions for people fighting cardiovascular disease as we have ever been. It's our Credo. It takes integrity, collaboration, innovation, and focus. We are leaders in the design and manufacture of tissue replacement heart valves and repair products as well as advanced hemodynamic monitoring. We partner with physicians to innovate products designed to help patients live longer, healthier, and more productive lives.

Our work is both rewarding and a privilege. The importance of what we do defines our approach. We work together to create an environment where ideas can flourish and we provide our people with the resources, expertise and support to bring those ideas to life.

For our legal terms and trademarks, please visit: https://www.edwards.com/legal/legal-terms 

Embrella Cardiovascular

Vascular Architects

Middle Peak Medical

Caption Health

Edwards Lifesciences

Today, we announced our Q4 2023 and full-year financial results. Read our #earnings release for Forward-Looking Statements and Non-GAAP Reconciliations here: https://lnkd.in/gFR4zZWq

#EWearnings #FinancialResults

Our Q4 2023 and full-year #earnings conference call will begin in 1 hour. Follow the link to join us: https://lnkd.in/eXwf4GMn

#EWearnings #FinancialResults

Join us tomorrow at 2 p.m. for a live webcast where we will share our Q4 2023 and full-year #FinancialResults.

Follow the link to join us: https://lnkd.in/eXwf4GMn

#EWearnings #earnings

Today, #EdwardsGoesRed to raise awareness of #HeartDisease in women. More than one in three women is living with some form of cardiovascular disease, but it’s often not recognized as the greatest health risk for women. Join us in spreading the word and getting the facts about heart disease in women: https://lnkd.in/ers5jsD
 
#WearRedDay #HeartMonth #GoRedForWomen #OurHeartsBeatWithEdwards

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve: https://lnkd.in/e-d_MU73

NYSE:EW

Edwards Lifesciences Corporation

Last Close

86.96

23/04 20:00

Market Cap

44.42B

Beta: 1.01

Volume Today

2.66M

Avg: 3.25M

PE Ratio

36.59

PFCF: 66.37

Please Sign In To Use The Chat